Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB31F in healthy malaria-naïve adults
NCT04238689Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TB31F in malaria (5 arms), sponsored by Radboud University Medical Center. Primary endpoint: Adverse Events at 84 days. Started Feb 2020; status: completed.
02
Drugs
TB31F
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04238689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238689.